Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma

NCT02505269 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin Lymphoma

Interventions

DRUG: Brentuximab Vedotin
DRUG: Adriamycin
DRUG: Dacarbazine

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]